81. 先天性副腎皮質酵素欠損症 Disease details / Clinical trials / Drug dev / DR info

AAV BBP-631
   Adrenas Therapeutics Inc
      2021   Phase 1/Phase 2   NCT04783181   Australia;United States
Abiraterone acetate
   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
      2011   Phase 1   NCT01495910   United States
   University of Texas Southwestern Medical Center
      2023   Phase 2   NCT03548246   United States
      2017   Phase 1   NCT02574910   United States
ATR-101
   Millendo Therapeutics US, Inc.
      2018   Phase 2   EUCTR2017-004878-34-ES   Brazil;France;Israel;Spain
   Millendo Therapeutics, Inc.
      2018   Phase 2   EUCTR2017-004878-34-FR   Brazil;France;Israel;Spain
      2016   Phase 2   NCT02804178   United States
Bone balance measurements
   University Hospital, Caen
      2012   Phase 2/Phase 3   NCT02552251   France
Chronocort
   Diurnal Limited
      2022   Phase 3   NCT05299554   France;Japan;United States
      2018   Phase 3   NCT03532022   United States
      2016   Phase 3   NCT02716818   United States
      2011   Phase 1   NCT03051893   -
      2010   Phase 1   NCT03019614   -
      2007   Phase 1/Phase 2   NCT00519818   United States
   Diurnal Ltd
      2017   Phase 3   EUCTR2015-005448-32-SE   Denmark;France;Germany;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2015-005448-32-DK   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2015-005448-32-GB   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2015-000711-40-SE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2015-000711-40-NL   Denmark;Germany;Netherlands;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2015-000711-40-DK   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000711-40-GB   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
   Fujii Katsuya
      2022   Phase 3   JPRN-jRCT2031210491   France;Japan;US
   Neurocrine UK Limited
      2022   Phase 3   NCT05063994   France;Japan;United States
Chronocort 10MG
   Diurnal Limited
      2022   Phase 3   EUCTR2021-003668-29-FR   France;Japan;Turkey;United States
   Neurocrine UK Limited
      2022   Phase 3   EUCTR2021-004467-26-FR   France;Japan;United States
Chronocort 5MG
   Diurnal Limited
      2022   Phase 3   EUCTR2021-003668-29-FR   France;Japan;Turkey;United States
   Neurocrine UK Limited
      2022   Phase 3   EUCTR2021-004467-26-FR   France;Japan;United States
Chronocort® 10 MG
   Diurnal Ltd
      2017   Phase 3   EUCTR2015-005448-32-DE   Denmark;France;Germany;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2015-000711-40-DE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
Chronocort® 20 MG
   Diurnal Ltd
      2017   Phase 3   EUCTR2015-005448-32-DE   Denmark;France;Germany;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2015-000711-40-DE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
Chronocort® 5 MG
   Diurnal Ltd
      2017   Phase 3   EUCTR2015-005448-32-DE   Denmark;France;Germany;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2015-000711-40-DE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
CI-984, 17aa70, PD 132301-2
   Millendo Therapeutics US, Inc.
      2018   Phase 2   EUCTR2017-004878-34-ES   Brazil;France;Israel;Spain
   Millendo Therapeutics, Inc.
      2018   Phase 2   EUCTR2017-004878-34-FR   Brazil;France;Israel;Spain
Cortef
   Diurnal Limited
      2007   Phase 1/Phase 2   NCT00519818   United States
   Neurocrine UK Limited
      2022   Phase 3   NCT05063994   France;Japan;United States
Cortef 10MG
   Diurnal Limited
      2022   Phase 3   EUCTR2021-003668-29-FR   France;Japan;Turkey;United States
Cortef 5MG
   Diurnal Limited
      2022   Phase 3   EUCTR2021-003668-29-FR   France;Japan;Turkey;United States
Corticotropin
   Neurocrine Biosciences, Inc.
      2021   Phase 3   EUCTR2020-004381-19-IT   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States
      2020   Phase 3   EUCTR2019-004873-17-IT   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
Cortisol
   Diurnal Ltd
      2017   Phase 3   EUCTR2015-005448-32-SE   Denmark;France;Germany;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2015-005448-32-DK   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2015-005448-32-DE   Denmark;France;Germany;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2015-005448-32-GB   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2015-000711-40-SE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2015-000711-40-NL   Denmark;Germany;Netherlands;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2015-000711-40-DK   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2015-000711-40-DE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000711-40-GB   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
Cortison
   Haukeland University Hospital
      2012   Phase 2   EUCTR2011-005822-23-NO   Norway;Sweden
Cortisone acetate
   Federico II University
      2016   Phase 4   NCT03760835   Italy
   Haukeland University Hospital
      2013   Phase 2   NCT01771328   Norway
Crinecerfont
   Neurocrine Biosciences
      2021   Phase 3   NCT04806451   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;United Kingdom;United States
      2020   Phase 3   NCT04490915   Austria;Belgium;Bulgaria;Canada;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;United Kingdom;United States
      2019   Phase 2   NCT04045145   United States
   Neurocrine Biosciences, Inc.
      2021   Phase 3   EUCTR2020-004381-19-IT   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States
      2021   Phase 3   EUCTR2020-004381-19-GR   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States
      2021   Phase 3   EUCTR2020-004381-19-FR   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States
      2021   Phase 3   EUCTR2020-004381-19-ES   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States
      2021   Phase 3   EUCTR2020-004381-19-DE   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004381-19-BE   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004873-17-NL   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004873-17-FR   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004873-17-DE   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004873-17-AT   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004873-17-PT   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004873-17-PL   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004873-17-IT   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004873-17-GB   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004873-17-CZ   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004873-17-BG   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Türkiye;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2020-004381-19-PL   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States
CRN04894
   Crinetics Pharmaceuticals Inc.
      2025   Phase 2   NCT06712823   United States
      2023   Phase 2   NCT05907291   Argentina;Brazil;Germany;India;Italy;United Kingdom;United States
Dectancyl
   Hospices Civils de Lyon
      2015   -   EUCTR2015-003996-32-FR   France
Dexamethasone
   Boston Children’s Hospital
      2008   Phase 2   NCT00621985   United States
   Federico II University
      2016   Phase 4   NCT03760835   Italy
   Shanghai Jiao Tong University School of Medicine
      2020   Phase 4   NCT04536662   China
Dexamethasone 0,1 MG tablets
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-DK   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
Dexamethasone 0.5MG tablet
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-DE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
Dexamethasone 1,5 MG tablets
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-NL   Denmark;Germany;Netherlands;Sweden;United Kingdom;United States
Dexamethasone 2MG tablets
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-SE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000711-40-GB   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
Diurf-006
   Diurnal Ltd
      2017   Phase 3   EUCTR2015-005448-32-SE   Denmark;France;Germany;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2015-005448-32-DK   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2015-005448-32-DE   Denmark;France;Germany;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2015-005448-32-GB   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2015-000711-40-SE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2015-000711-40-NL   Denmark;Germany;Netherlands;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2015-000711-40-DK   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2015-000711-40-DE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000711-40-GB   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
Efmody 10 MG modified release hard capsules
   Diurnal Limited
      2022   Phase 3   EUCTR2021-003668-29-FR   France;Japan;Turkey;United States
   Neurocrine UK Limited
      2022   Phase 3   EUCTR2021-004467-26-FR   France;Japan;United States
Efmody 5 MG modified release hard capsules
   Diurnal Limited
      2022   Phase 3   EUCTR2021-003668-29-FR   France;Japan;Turkey;United States
   Neurocrine UK Limited
      2022   Phase 3   EUCTR2021-004467-26-FR   France;Japan;United States
Fludrocortisone
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1995   Phase 4   NCT00001521   United States
   University of Texas Southwestern Medical Center
      2023   Phase 2   NCT03548246   United States
Flutamide
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1995   Phase 4   NCT00001521   United States
Hormonal balance measurements
   University Hospital, Caen
      2012   Phase 2/Phase 3   NCT02552251   France
Hydrocortisone
   Boston Children’s Hospital
      2008   Phase 2   NCT00621985   United States
   Diurnal Limited
      2016   Phase 3   NCT03062280   United States
      2015   Phase 3   EUCTR2015-000458-40-DE   Germany
      2015   Phase 3   EUCTR2014-002265-30-DE   Germany
      2010   Phase 1   NCT03019614   -
   Diurnal Ltd
      2017   Phase 3   EUCTR2015-005448-32-SE   Denmark;France;Germany;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2015-005448-32-DK   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
      2017   Phase 3   EUCTR2015-005448-32-DE   Denmark;France;Germany;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2015-005448-32-GB   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1995   Phase 4   NCT00001521   United States
   Federico II University
      2016   Phase 4   NCT03760835   Italy
   Fujii Katsuya
      2022   Phase 3   JPRN-jRCT2031210491   France;Japan;US
   Haukeland University Hospital
      2013   Phase 2   NCT01771328   Norway
   National Institutes of Health Clinical Center (CC)
      2013   Phase 2   NCT01859312   United States
   Radboud University Nijmegen Medical Centre
      2019   Phase 2   EUCTR2018-004802-24-NL   Netherlands
   Shanghai Jiao Tong University School of Medicine
      2020   Phase 4   NCT04536662   China
   University of Texas Southwestern Medical Center
      2023   Phase 2   NCT03548246   United States
Hydrocortisone - hydrocortisone tablet
   Spruce Biosciences Inc.
      2022   Phase 2   EUCTR2019-004765-40-IT   Australia;Canada;Denmark;Estonia;Germany;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Hydrocortisone 10MG tablet
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-DE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
Hydrocortisone 10MG tablets
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-DK   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
Hydrocortisone 20MG tablets
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-SE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2015-000711-40-NL   Denmark;Germany;Netherlands;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000711-40-GB   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
Hydrocortisone micronized
   Diurnal Limited
      2022   Phase 3   EUCTR2021-003668-29-FR   France;Japan;Turkey;United States
   Neurocrine UK Limited
      2022   Phase 3   EUCTR2021-004467-26-FR   France;Japan;United States
Hydrocortisone modified release capsules
   Diurnal Limited
      2012   Phase 2   NCT01735617   United States
Hydrocortisone sodium acetate
   Baylor College of Medicine
      2007   -   NCT00529841   United States
Hydrocortisone sodium phosphate
   University Hospitals Bristol NHS Foundation Trust
      2014   -   EUCTR2012-001104-37-GB   United Kingdom
Hydrocortisone sodium succinate
   Haukeland University Hospital
      2014   Phase 2   EUCTR2011-005822-23-SE   Norway;Sweden
Hydrocortisone tablet 2.5 MG
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-DK   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
Hydrocortisone withdrawal
   Maria I. New
      2007   -   NCT00542841   Brazil;France;United States
Hydrocortisone- hydrocortisone tablet
   Spruce Biosciences Inc.
      2022   Phase 2   EUCTR2019-004764-22-IT   Australia;Canada;Denmark;Germany;Italy;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;United Kingdom;United States
Idrocortisone
   Spruce Biosciences Inc.
      2022   Phase 2   EUCTR2019-004765-40-IT   Australia;Canada;Denmark;Estonia;Germany;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2022   Phase 2   EUCTR2019-004764-22-IT   Australia;Canada;Denmark;Germany;Italy;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;United Kingdom;United States
Infacort
   Diurnal Limited
      2016   Phase 3   NCT02733367   Germany
      2015   Phase 3   EUCTR2015-000458-40-DE   Germany
      2015   Phase 3   EUCTR2014-002265-30-DE   Germany
Letrozole
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1995   Phase 4   NCT00001521   United States
LU AG13909
   H. Lundbeck A/S
      2022   Phase 1   NCT05669950   Sweden;United Kingdom
Metabolic balance measurements
   University Hospital, Caen
      2012   Phase 2/Phase 3   NCT02552251   France
Metformin hydrochloride
   Ghent University Hospital
      2014   Phase 3   EUCTR2013-002395-40-BE   Belgium
Metformine sandoz 850 MG filmomhulde tabletten
   Ghent University Hospital
      2014   Phase 3   EUCTR2013-002395-40-BE   Belgium
Monitor
   Fujii Katsuya
      2022   Phase 3   JPRN-jRCT2031210491   France;Japan;US
NBI-74788
   Neurocrine Biosciences
      2018   Phase 2   NCT03525886   United States
   Neurocrine Biosciences, Inc.
      2021   Phase 3   EUCTR2020-004381-19-IT   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States
      2021   Phase 3   EUCTR2020-004381-19-GR   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States
      2021   Phase 3   EUCTR2020-004381-19-FR   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States
      2021   Phase 3   EUCTR2020-004381-19-ES   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States
      2021   Phase 3   EUCTR2020-004381-19-DE   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004381-19-BE   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004873-17-NL   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004873-17-FR   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004873-17-DE   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004873-17-AT   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004873-17-PT   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004873-17-PL   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004873-17-IT   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004873-17-GR   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004873-17-GB   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004873-17-CZ   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004873-17-BG   Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Türkiye;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2020-004381-19-PL   Belgium;Canada;France;Germany;Greece;Italy;Poland;Spain;Sweden;United States
NBI-77860
   Neurocrine Biosciences
      2015   Phase 1   NCT02349503   United States
Nevanimibe hydrochloride
   Millendo Therapeutics US, Inc.
      2018   Phase 2   NCT03669549   Brazil;Czechia;France;Israel;Spain
      2018   Phase 2   EUCTR2017-004878-34-ES   Brazil;France;Israel;Spain
   Millendo Therapeutics, Inc.
      2018   Phase 2   EUCTR2017-004878-34-FR   Brazil;France;Israel;Spain
Nifedipine
   National Center for Research Resources (NCRR)
      -   Phase 1/Phase 2   NCT00000102   United States
Pioglitazone
   Radboud University
      2005   -   NCT00151710   Netherlands
Prednisolone
   Federico II University
      2016   Phase 4   NCT03760835   Italy
   Haukeland University Hospital
      2014   Phase 2   EUCTR2011-005822-23-SE   Norway;Sweden
      2012   Phase 2   EUCTR2011-005822-23-NO   Norway;Sweden
Prednisolone - prednisolone tablet
   Spruce Biosciences Inc.
      2022   Phase 2   EUCTR2019-004765-40-IT   Australia;Canada;Denmark;Estonia;Germany;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Prednisolone 1MG tablets
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-SE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000711-40-GB   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
Prednisolone 2,5 MG tablets
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-DK   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
Prednisolone 5 MG tablets
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-NL   Denmark;Germany;Netherlands;Sweden;United Kingdom;United States
Prednisolone 5MG tablet
   Diurnal Ltd
      2016   Phase 3   EUCTR2015-000711-40-DE   Denmark;France;Germany;Netherlands;Sweden;United Kingdom;United States
Prednisone
   Federico II University
      2016   Phase 4   NCT03760835   Italy
   Shanghai Jiao Tong University School of Medicine
      2020   Phase 4   NCT04536662   China
Quality OF life assessment
   University Hospital, Caen
      2012   Phase 2/Phase 3   NCT02552251   France
SOLU-cortef
   Haukeland University Hospital
      2014   Phase 1/Phase 2   NCT02096510   Norway
      2014   Phase 2   EUCTR2011-005822-23-SE   Norway;Sweden
      2012   Phase 2   EUCTR2011-005822-23-NO   Norway;Sweden
SPR001
   Spruce Biosciences
      2018   Phase 2   NCT03687242   United States
      2017   Phase 2   NCT03257462   United States
   Spruce Biosciences Inc.
      2022   Phase 2   EUCTR2019-004765-40-IT   Australia;Canada;Denmark;Estonia;Germany;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2022   Phase 2   EUCTR2019-004764-22-IT   Australia;Canada;Denmark;Germany;Italy;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;United Kingdom;United States
   Spruce Biosciences, Inc.
      2023   Phase 2   EUCTR2019-004765-40-LV   Australia;Canada;Denmark;Estonia;Germany;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2023   Phase 2   EUCTR2019-004764-22-LV   Australia;Canada;Denmark;Estonia;Germany;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2022   Phase 2   EUCTR2019-004765-40-RO   Australia;Brazil;Canada;Denmark;Estonia;Germany;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Türkiye;United Kingdom;United States
      2022   Phase 2   EUCTR2019-004765-40-LT   Australia;Canada;Denmark;Estonia;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2022   Phase 2   EUCTR2019-004765-40-EE   Australia;Canada;Denmark;Estonia;Germany;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2022   Phase 2   EUCTR2019-004764-22-RO   Australia;Brazil;Canada;Denmark;Estonia;Germany;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Türkiye;United Kingdom;United States
      2022   Phase 2   EUCTR2019-004764-22-LT   Australia;Canada;Denmark;Estonia;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2019-004765-40-PL   Australia;Canada;Denmark;Estonia;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2019-004764-22-PL   Australia;Canada;Denmark;Estonia;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004765-40-SE   Australia;Canada;Denmark;Estonia;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004765-40-NL   Australia;Canada;Denmark;Estonia;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004765-40-DK   Australia;Canada;Denmark;Estonia;France;Germany;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004765-40-DE   Australia;Canada;Denmark;Estonia;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004764-22-SE   Australia;Canada;Denmark;Estonia;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004764-22-NL   Australia;Canada;Denmark;Estonia;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004764-22-GB   Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004764-22-DK   Australia;Canada;Denmark;Estonia;Germany;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004764-22-DE   Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
Standard care
   Diurnal Limited
      2018   Phase 3   NCT03532022   United States
Standard glucocorticoid therapy
   Diurnal Limited
      2016   Phase 3   NCT02716818   United States
   University of Minnesota
      2019   Phase 1   NCT03718234   United States
Subcutaneous hydrocortisone
   University of Minnesota
      2019   Phase 1   NCT03718234   United States
Tildacerfont
   Spruce Biosciences
      2021   Phase 2   NCT05128942   United States
      2020   Phase 2   NCT04544410   Australia;Brazil;Canada;Denmark;Estonia;Germany;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 2   NCT04457336   Australia;Brazil;Canada;Denmark;Estonia;Germany;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
   Spruce Biosciences Inc.
      2022   Phase 2   EUCTR2019-004765-40-IT   Australia;Canada;Denmark;Estonia;Germany;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2022   Phase 2   EUCTR2019-004764-22-IT   Australia;Canada;Denmark;Germany;Italy;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;United Kingdom;United States
   Spruce Biosciences, Inc.
      2023   Phase 2   EUCTR2019-004765-40-LV   Australia;Canada;Denmark;Estonia;Germany;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2023   Phase 2   EUCTR2019-004764-22-LV   Australia;Canada;Denmark;Estonia;Germany;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2022   Phase 2   EUCTR2019-004765-40-RO   Australia;Brazil;Canada;Denmark;Estonia;Germany;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Türkiye;United Kingdom;United States
      2022   Phase 2   EUCTR2019-004765-40-LT   Australia;Canada;Denmark;Estonia;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2022   Phase 2   EUCTR2019-004765-40-EE   Australia;Canada;Denmark;Estonia;Germany;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2022   Phase 2   EUCTR2019-004764-22-RO   Australia;Brazil;Canada;Denmark;Estonia;Germany;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Türkiye;United Kingdom;United States
      2022   Phase 2   EUCTR2019-004764-22-LT   Australia;Canada;Denmark;Estonia;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2019-004765-40-PL   Australia;Canada;Denmark;Estonia;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2019-004764-22-PL   Australia;Canada;Denmark;Estonia;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004765-40-SE   Australia;Canada;Denmark;Estonia;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004765-40-NL   Australia;Canada;Denmark;Estonia;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004765-40-DK   Australia;Canada;Denmark;Estonia;France;Germany;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004765-40-DE   Australia;Canada;Denmark;Estonia;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004764-22-SE   Australia;Canada;Denmark;Estonia;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004764-22-NL   Australia;Canada;Denmark;Estonia;Germany;Italy;Latvia;Lithuania;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004764-22-GB   Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004764-22-DK   Australia;Canada;Denmark;Estonia;Germany;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004764-22-DE   Australia;Canada;Denmark;France;Germany;Netherlands;Poland;Spain;Sweden;United Kingdom;United States